UltraGreen.ai Raises $188M as IPO Plans Gain Traction

In September 2025, UltraGreen.ai secured $188 million in funding at a $1.3 billion valuation. The raise strengthens the company’s efforts to expand its surgical imaging and fluorescence-guided technology platform.

A month earlier, in August 2025, reports emerged that the company was preparing for an IPO in Singapore, with a target of raising between S$300 million and S$400 million. While still under consideration, the listing would mark a significant step in scaling its operations globally.

UltraGreen.ai’s portfolio includes Diagnostic GreenDealroom has a profile for this one. Try Dealroom →’s Indocyanine Green (ICG) injection, the IC-Flow handheld imaging device, and software tools such as UltraLinQ. The acquisition of Perfusion TechDealroom has a profile for this one. Try Dealroom → in 2025 added real-time perfusion quantification, while links to companies such as Renew HealthDealroom has a profile for this one. Try Dealroom → and LifeSignals extend its reach across diagnostics and connected health.

With Asia—particularly Southeast Asia—highlighted as a priority, the fresh capital and potential IPO provide a platform for UltraGreen.ai to accelerate regulatory approvals, strengthen manufacturing, and extend adoption of its technologies in surgical settings worldwide.

Sources:
Bloomberg
Business Times
Forbes
Ultragreen.ai
Tech in Asia

J.V.